Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
PEGylated glucagon-like peptide-1 shows promise as a glucose-lowering agent
August 7th, 2006
PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. According to a study from South Korea, "The rapid degradation and clearance of glucagon-like peptide-1 (GLP-1) by the enzymes dipeptidyl peptidase-IV and neutral endopeptidase 24.11 are the main impediments to the development of GLP-1 as a potential glucose-lowering agent. In this study, new enzyme-resistant polyethylene glycol (PEG)-conjugated GLP-1 analogues were designed and examined for metabolic stability and biological potency." "Two mono-PEGylated GLP-1 analogues, N-terminally modified...
Source: Gastroenterology Week (2006-08-07)
|
